Purtscher RetinopathyNCT05350384
An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy
An observational study of Purtscher Retinopathy and Pancreatic Cancer, run by University of Catania at 1 site in Italy.
Trial summary
AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Purtscher Retinopathy, Pancreatic Cancer
- What is being tested?
- Methylprednisolone
- How many people
- 1 participants
- Where
- 1 siteItaly
- Study dates
- 18 Jun 2021to 1 Nov 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Study population: No population, only one patient
Who may be able to join
None listed.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy: Presentation of a Unique Case
AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY
Read the detailed description
Purtscher's retinopathy may cause sudden loss of vision of varying severity, secondary to head or chest injury. Its pathophysiology is unclear. Purtscher's-like retinopathy has more attenuated clinical and objective features and can be associated with many non-neoplastic pathologies.
Otherwise, an association of this kind of retinopathy with malignancies has been described once in the Literature (multiple myeloma). We present a case report on a unique association between pancreatic cancer and Purtscher-type retinopathy.
- Conditions
- Purtscher Retinopathy, Pancreatic Cancer
- Being tested
- Methylprednisolone
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
What is being measured
The primary outcome is the main question the study is designed to answer.
funduscopic examination
At the funduscopic examination the back of the eye showed large yellow spots and retinal hemorrhages in the superficial retina. In the early stages, fluorescein angiography showed hypofluorescence in the area of the yellow-white patches while the late stages showed hyperfluorescence
Measured: at the onset of symptoms
Secondary outcomes (1)
abdominal CT-scan
CT scan of the abdomen revealed a large mass in the tail of the pancreas with direct extension to the vessels of splenic hilum and splenic vein thrombosis. A secondary invasion of the gastric wall and left adrenal gland was also demonstrated. Percutaneous needle biopsy was performed and histopathology showed moderate to poorly differentiated mucinous pancreatic adenocarcinoma.
Measured: at the onset of symptoms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2022
- Study start18 Jun 2021
- Primary completion31 Jul 2021
- Study completion1 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Purtscher RetinopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Catania
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eva Intagliata, University of Catania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05350384
- Sponsor's protocol ID
- UCatania666
- Status last verified
- Apr 2022
- First submitted
- 14 Apr 2022
- Last updated
- 28 Apr 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Unusual Association Between Pancreatic Cancer and Purtscher-like Retinopathy: Presentation of a Unique Case
- ClinicalTrials.gov ID
- NCT05350384
- Acronym / sponsor ID
- UCatania666
- Conditions
- Purtscher Retinopathy, Pancreatic Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- University of CataniaUniversity, hospital or other
- Study start
- 18 Jun 2021 (actual)
- Primary completion
- 31 Jul 2021 (actual)
- Study completion
- 1 Nov 2021 (actual)
- First posted
- 28 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AN UNUSUAL ASSOCIATION BETWEEN PANCREATIC CANCER AND PURTSCHER-LIKE RETINOPATHY
Detailed description
Purtscher's retinopathy may cause sudden loss of vision of varying severity, secondary to head or chest injury. Its pathophysiology is unclear. Purtscher's-like retinopathy has more attenuated clinical and objective features and can be associated with many non-neoplastic pathologies.
Otherwise, an association of this kind of retinopathy with malignancies has been described once in the Literature (multiple myeloma). We present a case report on a unique association between pancreatic cancer and Purtscher-type retinopathy.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- No population, only one patient
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Methylprednisolone1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days | Drug | – |
Primary outcome
funduscopic examination
Time frame: at the onset of symptoms
At the funduscopic examination the back of the eye showed large yellow spots and retinal hemorrhages in the superficial retina. In the early stages, fluorescein angiography showed hypofluorescence in the area of the yellow-white patches while the late stages showed hyperfluorescence
1 secondary outcome
abdominal CT-scan
Time frame: at the onset of symptoms
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2022.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Purtscher Retinopathy and Pancreatic Cancer, run by University of Catania at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
funduscopic examination (time frame: at the onset of symptoms). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2022.